Menu Search
Equities

Gaush Meditech Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
F7Y:FRA

Gaush Meditech Ltd

Actions
  • Price (EUR)0.75
  • Today's Change-0.005 / -0.66%
  • Shares traded600.00
  • 1 Year change-34.78%
  • Beta--
Data delayed at least 15 minutes, as of Feb 16 2026 07:03 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Gaush Meditech Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of ophthalmic medical devices and consumables. The Company operates through four segments. The Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently. The Distribution Products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by other ophthalmic medical equipment manufacturers. The Technical Services segment provides warranty services, maintenance services and consumables used in after-sales services. The Other segment primarily include the licensing out of intellectual properties, as well as providing services related to Clinical Research Organization (CRO).

  • Revenue in HKD (TTM)1.63bn
  • Net income in HKD115.40m
  • Incorporated1998
  • Employees819.00
  • Location
    Gaush Meditech LtdRoom 1901, Building AZhonghui Plaza, No.11 Dongzhimen South ABEIJING ChinaCHN
  • Websitehttps://www.gaush.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.